Antibody Drug Conjugates Market Report 2021-2031

Table of Content

---

1 Report Overview

1.1 Global Antibody Drug Conjugate Market Overview

1.2 Study Goals and Objectives

1.3 Why it is Important to Study This Market?

1.4 What is the Scope of this Report?

1.5 Market Definitions

1.5.1 Antibody

1.5.2 Antigen

1.5.3 Cytotoxicity

1.5.4 Endocytosis

1.5.5 Immune system

1.5.6 Hybridoma Technology

1.5.7 Antibody drug conjugates (ADCs)

1.6 Why You Should Read This Report

1.7 How This Report Delivers

1.8 Key Questions Answered by This Analytical Report Include:

1.9 Who is This Report for?

1.10 Methodology

1.10.1 Primary Research

1.10.2 Secondary Research

1.11 Market Segmentation

1.12 Frequently Asked Questions (FAQ)

 

2 Executive Summary

2.1 What are the Advantages of ADCs

 

3 Antibody Drug Conjugate Technology Background

3.1 Overview

3.2 The Action Mechanism of ADC

3.3 Components of ADCs

3.4 How ADCs Work?

3.5 Antibody Drug Conjugation Technologies

3.5.1 How Good are Cysteine Conjugation?

3.5.2 Conjugation Methods Overview

3.5.3 Cysteine-Based Conjugation

3.5.4 Lysine-Based Conjugation

3.5.5 Site-Specific Conjugation

3.6 Types of Monoclonal Antibodies

 

4 What is the Current Status of ADCs Market?

4.1 FDA Approved Antibody Drug Conjugates

4.2 ADCs for Clinical Research in the Global Market

4.3 Innovative Linker Technology for Antibody Drug Conjugates (ADCs)

4.4 SWOT Analysis of Antibody Drug Conjugates Market

4.4.1 Strengths of ADC Market

4.4.1.1 The unique targeting capabilities and promising clinical trial results

4.4.1.2 Advances in targeting antibodies, potent payloads and drug-linker technologies

4.4.1.3 The growing number of cancer patients and increasing demand for biologics for the treatment

4.4.2 Weaknesses of ADC Market

4.4.2.1 dose-limiting toxicities such as liver toxicity or neutropenia

4.4.2.2 disulfide-based linkers suffer from premature loss of payload cargo

4.4.2.3 leading to less drug delivered to the tumor and more toxicity

4.4.3 Opportunities in the ADC Market

4.4.3.1 an innovative class of drugs that are mainly developed by conjugating already

4.4.3.2 have the potential to replace conventional treatment options

4.4.3.3 Most pharmaceutical companies are investing in the ADC industry

4.4.4 Threats in the ADC Market

4.4.4.1 The development of any drug is no simple matter, and it is even more complex for ADCs

4.4.4.2 ADC mechanistic pathway consists of a complicated sequence of events

4.4.4.3 Pathway complexity is the main reason so many previous attempts have been unsuccessful

4.5 Porter’s Five Forces Analysis

4.5.1 Threat of New Entrants (High)

4.5.2 Rivalry Among the Existing Players (Low)

4.5.3 Bargaining Power of Suppliers (High)

4.5.4 Threats from Substitute Products (Moderate to High)

4.5.5 Bargaining Power of Buyers (Low)

 

5 Which Factors Are Driving or Restraining the Growth of the Market?

5.1 Which are Market Driving Forces?

5.1.1 Is Patent Expiration a Master Key to Enter Global Market?

5.1.2 Targeted Nature of ADCs is Promising

5.1.3 How Increased Research on ADC Development Will Help the Market to Grow?

5.1.4 How Technological Advancements Are Driving Growth?

5.1.5 ADC Industry Involves a Specialization Business Model

5.1.6 Will Innovation in ADCs Disrupt the Market in Future?

5.1.7 Other Factors Boosting the Market Growth

5.2 Which Barriers Are Restraining the Market Growth?

5.2.1 Is Complexity of ADCs hindering its Growth?

5.2.2 Which are the Regulatory Issues Associated with ADC Products?

5.2.3 Regulatory Exclusivity

5.2.4 Which Challenges Companies have to Face in the Global Market?

5.3 What are the Opportunities in the Global Market?

5.3.1 Growth in Number of Cancer Patients in the World

5.3.2 Increasing Cost of Cancer Treatment

 

6 Global Market Outlook (COVID Impact Recovery Analysis)

6.1 How Much Worth is the Global Antibody Drug Conjugate Market?

6.2 Which Region is Leading the Antibody Drug Conjugate Market?

6.3 Global ADC Market Analysis by Technology

6.3.1 Is Cleavable Linkers Really in Demand?

6.3.2 Type of Linkers

6.4 Global ADC Market Analysis by Payload Type

6.4.1 Why MMAE Payload is Gaining More Traction than Others?

6.4.2 Types of Payloads (Cytotoxic Agents)

6.4.3 MMAE

6.4.4 DM4

6.4.5 Camptothecin

6.4.6 DM1

6.4.7 MMAF

6.5 Global ADC Market Analysis by Target Antigen

6.5.1 CD19

6.5.2 CD20

6.5.3 CD22

6.5.4 CD25

6.5.5 CD30

6.5.6 CD33

6.5.7 CD40

6.5.8 CD56

6.5.9 CD74

6.5.10 CD79a and CD79b

6.5.11 CD138 (Syndecan-1)

6.5.12 CEACAM (Carcinoembryonic Antigen-Related Cell Adhesion Molecule)

6.5.13 EGFR (Epidermal Growth Factor Receptor/ERBB1)

6.5.14 EGP-1 (Epithelial Glycoprotein-1 Antigen)

6.5.15 GPNMB

6.5.16 LIV-1

6.5.17 Mesothelin

6.5.18 Nectin-4

6.5.19 Prostate-Specific Membrane Antigen (PSMA)

6.5.20 SLITRK6

6.5.21 VEGF (Vascular Endothelial Growth Factor)

6.5.22 HER2 Targeting ADCs

6.6 Global ADC Market Analysis by Drug Type

6.6.1 Adcetris

6.6.2 Kadcyla

6.7 Global Antibody Drug Conjugates Market Analysis by Linker Type

6.7.1 Valine-Citrulline (VC)

6.7.2 Sulfo-SPDB

6.7.3 SMCC

6.7.4 VA

6.7.5 Hydrazone

6.8 Which Application is Driving More Demand for Antibody Drug Conjugate Market?

6.8.1 ADC Application Overview

6.8.2 Breast Cancer

6.8.3 Lymphoma

6.8.4 Other Types of Cancer

 

7 North America Market Outlook (COVID Impact Recovery Analysis)

7.1 How North America is Dominating the Global Antibody Drug Conjugate Market?

7.2 North America Antibody Drug Conjugates Market by Country

7.3 US Antibody Drug Conjugate Market Outlook

7.4 Canada Antibody Drug Conjugate Market Outlook

7.5 North America Antibody Drug Conjugates Market by Technology

7.6 North America Antibody Drug Conjugates Market by Payload Type

7.7 North America Antibody Drug Conjugates Market by Target Antigen

7.8 North America Antibody Drug Conjugates Market by Drug

7.9 North America Antibody Drug Conjugates Market Analysis by Linker Type

7.10 North America Antibody Drug Conjugates Market by Application

 

8 Europe Market Outlook (COVID Impact Recovery Analysis)

8.1 How Much Worth is the Antibody Drug Conjugate Market in Europe?

8.2 Europe Antibody Drug Conjugates Market by Country

8.3 How Russia ADC Market is Performing?

8.4 What is the Status of Germany Market?

8.5 How Much Value Does UK ADC Market Holds?

8.6 How Much to Expect from France ADC Market?

8.7 What is the Growth Rate of Italy ADC Market?

8.8 Rest of Europe ADC Market Outlook

8.9 Europe Antibody Drug Conjugates Market by Technology

8.10 Europe Antibody Drug Conjugates Market by Payload Type

8.11 Europe Antibody Drug Conjugates Market by Target Antigen

8.12 Europe Antibody Drug Conjugates Market by Drug

8.13 Europe Antibody Drug Conjugates Market by Linker Type

8.14 Europe Antibody Drug Conjugates Market by Application

 

9 Asia-Pacific Market Outlook (COVID Impact Recovery Analysis)

9.1 How Big is the Asia-Pacific Market in Terms of Value?

9.2 Is Japan Really Leading the Antibody Drug Conjugate Market in the Region?

9.3 Why Japan is Holding Strong Position in the Region?

9.4 How Big is the China ADC Market?

9.5 Why ADC Market in India is Growing at Faster Rate?

9.6 How South Korea Market is Performing?

9.7 Is Australia ADC Market Worth Investing?

9.8 Rest of Asia-Pacific ACD Market Outlook

9.9 Asia-Pacific Antibody Drug Conjugates Market by Technology

9.10 Asia-Pacific Antibody Drug Conjugates Market by Payload Type

9.11 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen

9.12 Asia-Pacific Antibody Drug Conjugates Market by Drug

9.13 Asia-Pacific Antibody Drug Conjugates Market by Linker Type

9.14 Asia-Pacific Antibody Drug Conjugates Market by Application

 

10 LAMEA Market Outlook (COVID Impact Recovery Analysis)

10.1 What is the Status of Antibody Drug Conjugate Market in the Region?

10.2 LAMEA Antibody Drug Conjugates Market by Country

10.3 Is Brazil Leading ADC Market in the LAMEA Region?

10.4 How Much Worth is Saudi Arabia ADC Market?

10.5 Are there Any Opportunities in the South Africa ADC Market?

10.6 How Mexico ADC Market is Performing?

10.7 UAE ADC Market Outlook

10.8 Rest of LAMEA Market Outlook

10.9 LAMEA Antibody Drug Conjugates Market by Technology

10.10 LAMEA Antibody Drug Conjugates Market by Payload Type

10.11 LAMEA Antibody Drug Conjugates Market by Target Antigen

10.12 LAMEA Antibody Drug Conjugates Market by Drug

10.13 LAMEA Antibody Drug Conjugates Market by Linker Type

10.14 LAMEA Antibody Drug Conjugates Market by Application

 

11 Leading Company Profiles

11.1 Overview

11.2 AbbVie Inc. Company

11.2.1 Company Information

11.2.2 Company Overview

11.2.3 Company Financial Profile

11.2.4 Company Product Offerings

11.2.5 Company Recent Developments

11.3 Astellas Pharmaceuticals Company

11.3.1 Company Information

11.3.2 Company Overview

11.3.3 Company Financial Profile

11.3.4 Company Product Offerings

11.3.5 Company Recent Developments

11.4 Bayer Pharmaceuticals Company

11.4.1 Company Information

11.4.2 Company Overview

11.4.3 Company Financial Profile

11.4.4 Company Product Offerings

11.4.5 Company Recent Developments

11.5 Celldex Therapeutics Company

11.5.1 Company Information

11.5.2 Company Overview

11.5.3 Company Financial Profile

11.5.4 Company Recent Developments

11.6 Genentech Biotechnology Company

11.6.1 Company Information

11.6.2 Company Overview

11.6.3 Company Product Offerings

11.6.4 Company Recent Developments

11.7 ImmunoGen Biotechnology Company

11.7.1 Company Information

11.7.2 Company Overview

11.7.3 Company Financial Profile

11.7.4 Company Recent Developments

11.8 Immunomedics Inc. Company

11.8.1 Company Information

11.8.2 Company Overview

11.8.3 Company Financial Profile

11.8.4 Company Product Offerings

11.8.5 Company Recent Developments

11.9 Lonza Group AG Company

11.9.1 Company Information

11.9.2 Company Overview

11.9.3 Company Financial Profile

11.9.4 Company Product Offerings

11.9.5 Company Recent Developments

11.10 Mersana Therapeutics Inc. Company

11.10.1 Company Information

11.10.2 Company Overview

11.10.3 Company Financial Profile

11.10.4 Company Recent Developments

11.11 Takeda Pharmaceuticals Company Ltd.

11.11.1 Company Information

11.11.2 Company Overview

11.11.3 Company Financial Profile

11.11.4 Company Product Offerings

11.11.5 Company Recent Developments

11.12 Pfizer Inc Company

11.12.1 Company Information

11.12.2 Company Overview

11.12.3 Company Financial Profile

11.12.4 Company Product Offerings

11.12.5 Company Recent Developments

11.13 F. Hoffmann-La Roche Ltd Company

11.13.1 Company Information

11.13.2 Company Overview

11.13.3 Company Financial Profile

11.13.4 Company Product Offerings

11.13.5 Company Recent Developments

11.14 Lantheus Holdings Company

11.14.1 Company Information

11.14.2 Company Overview

11.14.3 Company Financial Profile

11.14.4 Company Product Offerings

11.14.5 Company Recent Developments

11.15 Seattle Genetics Company

11.15.1 Company Information

11.15.2 Company Overview

11.15.3 Company Financial Profile

11.15.4 Company Product Offerings

11.15.5 Company Recent Developments

11.16 Merck Group Chemicals Company

11.16.1 Company Information

11.16.2 Company Overview

11.16.3 Company Financial Profile

11.16.4 Company Product Offerings

11.16.5 Company Recent Developments

 

12 Antibody Drug Conjugate Product Pipeline Analysis

12.1 Manufacturer Strategies

12.2 1.Celldex Therapeutics.

12.3 Synthetic Modified Vaccines

12.3.1 Fully Synthetic Carbohydrate-Based Vaccines

12.3.2 A Synthetic Vaccine Against Meningococcal

12.3.3 Recent Development

 

13 Conclusion and Recommendations

13.1 List of Other Key Companies in the Market

13.2 List of Organizations Associated with Drugs

List of Figures

---

Figure 1.1 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)

Figure 3.1 Antibody Drug Conjugate Action Mechanism Overview

Figure 5.1 Global Cancer Cases Breakdown by Gender and Type, 2019

Figure 6.1 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)

Figure 6.2 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 6.3 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 6.4 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 6.5 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 6.6 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %)

Figure 6.7 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 6.8 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 6.9 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 6.10 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 6.11 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)

Figure 6.12 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 6.13 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 6.14 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 6.15 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 6.16 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 6.17 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 6.18 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 6.19 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 6.20 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 6.21 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)

Figure 6.22 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 6.23 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 6.24 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 6.25 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 6.26 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)

Figure 6.27 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 6.28 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 6.29 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 6.30 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 6.31 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 6.32 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 6.33 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 6.34 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 6.35 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 7.1 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)

Figure 7.2 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 7.3 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 7.4 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 7.5 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 7.6 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %)

Figure 7.7 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 7.8 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 7.9 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 7.10 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 7.11 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)

Figure 7.12 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 7.13 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 7.14 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 7.15 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 7.16 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 7.17 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 7.18 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 7.19 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 7.20 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 7.21 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)

Figure 7.22 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 7.23 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 7.24 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 7.25 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 7.26 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)

Figure 7.27 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 7.28 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 7.29 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 7.30 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 7.31 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 7.32 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 7.33 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 7.34 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 7.35 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 7.36 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %)

Figure 7.37 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 7.38 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 7.39 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 7.40 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 8.1 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)

Figure 8.2 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 8.3 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 8.4 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 8.5 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 8.6 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %)

Figure 8.7 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 8.8 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 8.9 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 8.10 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 8.11 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)

Figure 8.12 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 8.13 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 8.14 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 8.15 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 8.16 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 8.17 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 8.18 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 8.19 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 8.20 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 8.21 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)

Figure 8.22 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 8.23 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 8.24 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 8.25 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 8.26 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)

Figure 8.27 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 8.28 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 8.29 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 8.30 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 8.31 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 8.32 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 8.33 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 8.34 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 8.35 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 8.36 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %)

Figure 8.37 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 8.38 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 8.39 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 8.40 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 9.1 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)

Figure 9.2 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 9.3 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 9.4 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 9.5 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 9.6 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %)

Figure 9.7 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 9.8 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 9.9 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 9.10 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 9.11 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)

Figure 9.12 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 9.13 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 9.14 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 9.15 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 9.16 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 9.17 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 9.18 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 9.19 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 9.20 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 9.21 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)

Figure 9.22 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 9.23 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 9.24 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 9.25 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 9.26 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)

Figure 9.27 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 9.28 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 9.29 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 9.30 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 9.31 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 9.32 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 9.33 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 9.34 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 9.35 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 9.36 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %)

Figure 9.37 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 9.38 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 9.39 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 9.40 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 10.1 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)

Figure 10.2 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 10.3 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 10.4 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 10.5 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 10.6 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %)

Figure 10.7 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 10.8 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 10.9 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 10.10 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 10.11 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)

Figure 10.12 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 10.13 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 10.14 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 10.15 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 10.16 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 10.17 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 10.18 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 10.19 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 10.20 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 10.21 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)

Figure 10.22 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 10.23 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 10.24 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 10.25 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 10.26 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)

Figure 10.27 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 10.28 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 10.29 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 10.30 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 10.31 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)

Figure 10.32 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)

Figure 10.33 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)

Figure 10.34 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)

Figure 10.35 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)

Figure 10.36 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %)

Figure 10.37 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)

Figure 10.38 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)

Figure 10.39 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)

Figure 10.40 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)

Figure 11.1 AbbVie Inc: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.2 AbbVie Inc: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.3 AbbVie Inc: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.4 AbbVie Inc: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.5 Astellas Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.6 Astellas Pharmaceuticals: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.7 Astellas Pharmaceuticals: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.8 Astellas Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.9 Bayer Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.10 Bayer Pharmaceuticals: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.11 Bayer Pharmaceuticals: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.12 Bayer Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.13 Celldex Therapeutics: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.14 Celldex Therapeutics: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.15 Celldex Therapeutics: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.16 Celldex Therapeutics: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.17 ImmunoGen Biotechnology: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.18 ImmunoGen Biotechnology: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.19 ImmunoGen Biotechnology: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.20 ImmunoGen Biotechnology: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.21 Immunomedics Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.22 Immunomedics Inc. Company: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.23 Immunomedics Inc. Company: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.24 Immunomedics Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.25 Lonza Group AG: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.26 Lonza Group AG.: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.27 Lonza Group AG.: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.28 Lonza Group AG.: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.29 Mersana Therapeutics Inc: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.30 Mersana Therapeutics Inc. Company: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.31 Mersana Therapeutics Inc. Company: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.32 Mersana Therapeutics Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.33 Takeda Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.34 Takeda Pharmaceuticals: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.35 Takeda Pharmaceuticals: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.36 Takeda Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.37 Pfizer Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.38 Pfizer Inc. Company: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.39 Pfizer Inc. Company: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.40 Pfizer Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.41 La Roche Ltd. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.42 La Roche Ltd. Company: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.43 La Roche Ltd. Company: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.44 La Roche Ltd. Company: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.45 Lantheus Holdings Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.46 Lantheus Holdings Company: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.47 Lantheus Holdings Company: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.48 Lantheus Holdings Company: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.49 Seattle Genetics Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.50 Seattle Genetics Company: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.51 Seattle Genetics Company: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.52 Seattle Genetics Company: Company Net Income/Loss 2015-2019 (US$ Mn)

Figure 11.53 Merck Group Chemicals Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Figure 11.54 Merck Group Chemicals Company: Company Operating Income 2015-2019 (US$ Mn)

Figure 11.55 Merck Group Chemicals Company: Company EBITDA 2015-2019 (US$ Mn)

Figure 11.56 Merck Group Chemicals Company: Company Net Income/Loss 2015-2019 (US$ Mn)

 

List of Tables

---

Table 1.1 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 2.1 Global Antibody Drug Conjugate Market Summary

Table 2.2 Global Antibody Drug Conjugate Market by Drugs and FDA Approval Details

Table 3.1 Types of Antibody Drug Conjugates Based on Type of Monoclonal Antibody

Table 4.1 Global Antibody Drug Conjugate Market by Drugs and FDA Approval Details

Table 4.2 60 ADC Projects Under Development In The Global Market

Table 5.1 Number of Cancer Cases in 2019

Table 6.1 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 6.2 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 6.3 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 6.4 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 6.5 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 6.6 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 6.7 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 6.8 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 6.9 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 6.10 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 6.11 Significant Antibody Drug Conjugate Linkers

Table 6.12 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 6.13 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 6.14 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 6.15 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 6.16 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 6.17 Significant Antibody Drug Conjugate Payloads

Table 6.18 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 6.19 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 6.20 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 6.21 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 6.22 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 6.23 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 6.24 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 6.25 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 6.26 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 6.27 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 6.28 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 6.29 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 6.30 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 6.31 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 6.32 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 6.33 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 6.34 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 6.35 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 6.36 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 6.37 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 7.1 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 7.2 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.3 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.4 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.5 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.6 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 7.7 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.8 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.9 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.10 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.11 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US$bilion, AGR %, CAGR %)

Table 7.12 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.13 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.14 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.15 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.16 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 7.17 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.18 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.19 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.20 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.21 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 7.22 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 7.23 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 7.24 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 7.25 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 7.26 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 7.27 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 7.28 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 7.29 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 7.30 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 7.31 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 7.32 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 7.33 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 7.34 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 7.35 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 7.36 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 7.37 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 7.38 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 7.39 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 7.40 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 7.41 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 7.42 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.43 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.44 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.45 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.1 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.2 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.3 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.4 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.5 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.6 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.7 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.8 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.9 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.10 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.11 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.12 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.13 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.14 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.15 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.16 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.17 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.18 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.19 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.20 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.21 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.22 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.23 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.24 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.25 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.26 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.27 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.28 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.29 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.30 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.31 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.32 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.33 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.34 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.35 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.36 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.37 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.38 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.39 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.40 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.41 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 8.42 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 8.43 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 8.44 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 8.45 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 8.46 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 8.47 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 8.48 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 8.49 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 8.50 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 8.51 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 8.52 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 8.53 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 8.54 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 8.55 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 8.56 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 8.57 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 8.58 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 8.59 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 8.60 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 8.61 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 8.62 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.63 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.64 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.65 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.1 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.2 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.3 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.4 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.5 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.6 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.7 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.8 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.9 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.10 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.11 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.12 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.13 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.14 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.15 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.16 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.17 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.18 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.19 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.20 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.21 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.22 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.23 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.24 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.25 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.26 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.27 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.28 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.29 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.30 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.31 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.32 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.33 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.34 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.35 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.36 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.37 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.38 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.39 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.40 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.41 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 9.42 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 9.43 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 9.44 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 9.45 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 9.46 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 9.47 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 9.48 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 9.49 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 9.50 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 9.51 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 9.52 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 9.53 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 9.54 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 9.55 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 9.56 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 9.57 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 9.58 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 9.59 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 9.60 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 9.61 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 9.62 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.63 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.64 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.65 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.1 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.2 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.3 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.4 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.5 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.6 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.7 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.8 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.9 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.10 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.11 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.12 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.13 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.14 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.15 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.16 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.17 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.18 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.19 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.20 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.21 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.22 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.23 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.24 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.25 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.26 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.27 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.28 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.29 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.30 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.31 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.32 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.33 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.34 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.35 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.36 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.37 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.38 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.39 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.40 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.41 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 10.42 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 10.43 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 10.44 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 10.45 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 10.46 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 10.47 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 10.48 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 10.49 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 10.50 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 10.51 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 10.52 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 10.53 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 10.54 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 10.55 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 10.56 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)

Table 10.57 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)

Table 10.58 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)

Table 10.59 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)

Table 10.60 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)

Table 10.61 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %)

Table 10.62 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.63 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.64 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.65 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 11.1 AbbVie Inc: Company Information

Table 11.2 AbbVie Inc: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.3 AbbVie Inc: Company Product and Service Offerings

Table 11.4 AbbVie Inc: Company Recent Developments till Sept,2020

Table 11.5 Astellas Pharmaceuticals: Company Information

Table 11.6 Astellas Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.7 Astellas Pharmaceuticals: Company Product and Service Offerings

Table 11.8 Astellas Pharmaceuticals: Company Recent Developments till Sept,2020

Table 11.9 Bayer Pharmaceuticals: Company Information

Table 11.10 Bayer Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.11 Bayer Pharmaceuticals: Company Product and Service Offerings

Table 11.12 Bayer Pharmaceuticals: Company Recent Developments till Sept,2020

Table 11.13 Celldex Therapeutics: Company Information

Table 11.14 Celldex Therapeutics: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.15 Celldex Therapeutics: Company Recent Developments till Sept,2020

Table 11.16 Genentech Biotechnology: Company Information

Table 11.17 Genentech Biotechnology: Company Product and Service Offerings

Table 11.18 Genentech Biotechnology: Company Recent Developments till Sept,2020

Table 11.19 ImmunoGen Biotechnology: Company Information

Table 11.20 ImmunoGen Biotechnology. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.21 ImmunoGen Biotechnology: Company Recent Developments till Sept,2020

Table 11.22 Immunomedics Inc: Company Information

Table 11.23 Immunomedics Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.24 Immunomedics Inc: Company Product and Service Offerings

Table 11.25 Immunomedics Inc: Company Recent Developments till Sept,2020

Table 11.26 Lonza Group AG: Company Information

Table 11.27 Lonza Group AG.: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.28 Lonza Group AG: Company Product and Service Offerings

Table 11.29 Lonza Group AG: Company Recent Developments till Sept,2020

Table 11.30 Mersana Therapeutics Inc: Company Information

Table 11.31 Mersana Therapeutics Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.32 Mersana Therapeutics Inc: Company Recent Developments till Sept,2020

Table 11.33 Takeda Pharmaceuticals: Company Information

Table 11.34 Takeda Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.35 Takeda Pharmaceuticals: Company Product and Service Offerings

Table 11.36 Takeda Pharmaceuticals: Company Recent Developments till Sept,2020

Table 11.37 Pfizer Inc: Company Information

Table 11.38 Pfizer Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.39 Pfizer Inc: Company Product and Service Offerings

Table 11.40 Pfizer Inc: Company Recent Developments till Sept,2020

Table 11.41 La Roche Ltd: Company Information

Table 11.42 La Roche Ltd. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.43 La Roche Ltd: Company Product and Service Offerings

Table 11.44 La Roche Ltd: Company Recent Developments till Sept,2020

Table 11.45 Lantheus Holdings: Company Information

Table 11.46 Lantheus Holdings Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.47 Lantheus Holdings: Company Product and Service Offerings

Table 11.48 Lantheus Holdings: Company Recent Developments till Sept,2020

Table 11.49 Seattle Genetics: Company Information

Table 11.50 Seattle Genetics Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.51 Seattle Genetics: Company Product and Service Offerings

Table 11.52 Seattle Genetics: Company Recent Developments till Sept,2020

Table 11.53 Merck Group Chemicals: Company Information

Table 11.54 Merck Group Chemicals Company: Company Revenue 2015-2019 (US$ Mn, AGR %)

Table 11.55 Merck Group Chemicals: Company Product and Service Offerings

Table 11.56 Merck Group Chemical: Company Recent Developments till Sept,2020

Table 12.1 AbbVie Inc: Company Product Pipeline

Table 12.2 Astellas Pharmaceutics: Company Product Pipeline

Table 12.3 Bayer Pharmaceutics: Company Product Pipeline

Table 12.4 Celldex Therapeutics: Company Product Pipeline

Table 12.5 Genentech Biotechnology: Company Product Pipeline

Table 12.6 ImmunoGen Biotechnology: Company Product Pipeline

Table 12.7 Immunomedics Inc: Company Product Pipeline

Table 12.8 Mersana Therapeutics: Company Product Pipeline

Table 12.9 Takeda Pharmaceuticals: Company Product Pipeline

Table 12.10 Pfizer Inc: Company Product Pipeline

Table 12.11 Roche Ltd: Company Product Pipeline

Table 12.12 Lantheus Holdings: Company Product Pipeline

Table 12.13 Seattle Genetics: Company Product Pipeline

Table 12.14 Merck Group Chemicals: Company Product Pipeline